Global Personalized Cell Therapeutic Market – Industry Trends and Forecast to 2030

Global Personalized Cell Therapeutic Market, By Cell Type (Embryonic Stem Cells, Adult Stem Cell, Induced Pluripotent Cells, Others), Application (Cardiovascular Diseases, Neurological Disorders, Diabetes, Oncology, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Personalized Cell Therapeutic Market Analysis and Size

The growing arena of advanced therapies and gene delivery technologies has created an increasingly competitive dynamic where a considerable number of market players are involved in commercializing their personalized cell therapeutic products. Personalized cell therapy has gained a push based on the adoption by the surgeon to treat the patient. The demand for the global personalized cell therapy market has increased the growth of the chronic disease ailment among patients.

Data Bridge Market Research analyses a growth rate in the global personalized cell therapeutic market in the forecast period 2023-2030. The expected CAGR of the global personalized cell therapeutic market tends to be around 24.00% in the mentioned forecast period. The market was valued at USD 12,572.34 million in 2022 and would grow to USD 93,671.26 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Personalized Cell Therapeutic Market Scope and Segmentation

Market Definition

Personalized cells are undifferentiated stem cells that can be divided to generate offspring cells designated as specialized or personalized stem cells. Specialized treatment of numerous chronic diseases such as autoimmune and cancer through vaccinating living cells into the body of patients to boost the personalized cell therapy market. As there are multiple types of living cells such as immature and mature living cell, blood and bone marrow cell and embryonic stem cells that are mainly utilized in personalized cell therapy.

Global Personalized Cell Therapeutic Market Dynamics

Drivers

• Increasing Economic Burden Due to Neurological Disorders

There are numerous studies conducted on stem cell or personalized cell therapy candidates to treat several neurological disorders and spinal cord injuries. For instance, in September 2016, MAPFRE Foundation declared its first clinical trial results of personalized cell therapy in patients having complete and chronic spinal cord injury. The study led to implanting mesenchymal stem cells that can create different types of tissue to treat the injury.

• Rising Cases of Chronic Diseases and Cancer

The increasing prevalence of chronic diseases and the collective occurrence of cancer is anticipated to boost the growth of the personalized cell therapy market during the forecast period. For instance, as per the National Cancer Institute (NCI), in 2016, there were an estimated 15.5 million cancer cases that have been occurred in the U.S. Furthermore, as per the records of NCI, in 2017, about 15,270 children and adolescents of the age group of 0 to 19 were diagnosed with cancer in the U.S. Additionally, according to the International Diabetes Federation (IDF), in 2017, over 425 million adults suffered from diabetes worldwide, and this is projected to reach 629 million by 2045. Thus, it boosts market growth.

Opportunities

• Increased Clinical Trials

Several manufacturers are conducting numerous clinical trials to develop novel personalized cell therapies targeting chronic diseases such as cancer, diabetes, and other autoimmune diseases. For instance, in April 2019, Orgenesis Inc. received Institutional Review Board (IRB) approval to collect liver biopsies from patients at Rambam Medical Center, Israel. The sample will be collected to confirm the safety and efficacy of liver cells for personalized cell replacement therapy in patients with insulin-dependent diabetes resulting from total or partial pancreatectomy. Thus, growing research studies are projected to boost the growth of the global personalized cell therapy market.

• Higher Strategic Alliances

Several companies are engaged in strategic alliances to boost their offerings in the space, which is projected to strengthen the market competition during the forecast period. For instance, in November 2021, Laurus Labs announced that an agreement was signed to invest in Immunoadoptive Cell Therapy (ImmunoACT), an IIT-Bombay incubated company developing an indigenous CAR T-cell therapy for the treatment of specific types of blood cancers. The Laurus Labs will acquire a 26.62% stake in ImmunoACT for a cash consideration of approximately ₹46 crores.

 Restraints/Challenges

• Risk of Complications

There is a high risk of complications associated with personalized cell therapies. Complications such as sleep apnea, skin reactions, increased risk of blood clots, and many others are witnessed post the therapy. Thus, it hampers market growth.

• High Cost

The huge expenditure associated with gene therapies impedes the market growth. Most personalized cell therapeutic products are in the U.S. are covered under reimbursement policies. However, patients who do not have insurance find it difficult to afford such treatments.

This global personalized cell therapeutic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global personalized cell therapeutic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In December 2021, Kite and Daiichi Sankyo Company announced the launch of YESCARTA. It is a chimeric antigen receptor (CAR) T-cell therapy, that will be available to patients suffering from relapsed or refractory large B-cell lymphomas in Japan. 

Global Personalized Cell Therapeutic Market Scope

The global personalized cell therapeutic market is segmented on the basis of cell type, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cell Type

• Embryonic Stem Cells
• Adult Stem Cell
• Induced Pluripotent Cells
• Others

Application

• Cardiovascular Diseases
• Neurological Disorders
• Diabetes
• Oncology
•  Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Personalized Cell Therapeutic Market Regional Analysis/Insights

The global personalized cell therapeutic market is analyzed and market size insights and trends are provided by cell type, application, distribution channel and end-user as referenced above.

The major countries covered in the global personalized cell therapeutic market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing positive growth for the personalized cell therapeutic market throughout the forecast period due to the region's increased R&D activities on personalized cells and well-established healthcare infrastructure.

Asia-Pacific dominates the market due to increased technological advancement and the increasing prevalence of chronic and metabolic diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Personalized Cell Therapeutic Market Share Analysis

The personalized cell therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to personalized cell therapeutic market

Key players operating in the personalized cell therapeutic market include:

• AbbVie Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Cipla Inc. (India)
• Lupin (India)
• Sun Pharmaceuticals Industries Ltd. (India)
• Hikma Pharmaceuticals PLC (U.K.)
• AstraZeneca (U.K.)
• GSK Plc. (U.K.)
• Pfizer Inc. (U.S.)
• Amneal Pharmaceuticals LLC. (U.K.)
• Alvogen (U.S)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Amgen Inc. (U.S.)
• Jazz Pharmaceuticals, Inc. (U.K.)
• Amicus Therapeutics, Inc (U.S.)
• MeiraGTx Limited (U.S.)
• Rocket Pharmaceuticals, Inc. (U.S.)
• Gilead Sciences, Inc. (U.S.)

Research Methodology: Global Personalized Cell Therapeutic Market    

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.